PAR · ALTHX.PA
THX Pharma
€3.48+€0.02 (+0.58%)
THX Pharma’s quoted price sits in the upper half of its reported 52-week range, 31.76% below the high.
Loading market information…
PAR · AELIS.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:08 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Aelis Farma S.A.’s quoted price sits in the lower half of its reported 52-week range, 67.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Aelis Farma S.A.’s next earnings report is currently expected on Apr 5, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aelis Farma S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-specific inhibitors that target CB1 receptors. Its leading investigational drug, AEF0117, is currently advancing through Phase 2b clinical trials, designed to alleviate the harmful impacts of excessive cannabis consumption. Furthermore, AEF0217, another key drug candidate, has successfully completed Phase 1 clinical trials, with the goal of addressing cognitive impairments linked to Down syndrome and other similar conditions.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€3.48+€0.02 (+0.58%)
THX Pharma’s quoted price sits in the upper half of its reported 52-week range, 31.76% below the high.
€0.65+€0.02 (+3.67%)
Valbiotis S.A.’s quoted price sits in the lower half of its reported 52-week range, 50.08% below the high.
€0.14+€0.02 (+16.5%)
TME Pharma N.V.’s quoted price sits in the upper half of its reported 52-week range, 19.93% below the high.
€0.07-€0.00 (-1.07%)
GenSight Biologics S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.91% below the high.
€0.20-€0.00 (-0.98%)
Intrasense S.A.’s quoted price sits in the lower half of its reported 52-week range, 57.11% below the high.
€0.69+€0.02 (+2.53%)
Advicenne S.A.’s quoted price sits in the lower half of its reported 52-week range, 70.64% below the high.
€0.17+€0.01 (+6.46%)
Poxel S.A.’s quoted price sits in the lower half of its reported 52-week range, 64.29% below the high.
€0.40-€0.02 (-4.98%)
NFL Biosciences S.A.’s quoted price sits in the lower half of its reported 52-week range, 78.32% below the high.
